Weight | 1 lbs |
---|---|
Dimensions | 9 × 5 × 2 in |
accession | P04155 |
express system | HEK293 |
product tag | C-hFc |
purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC |
background | Breast cancer (BC) is the most common cancer in women and the second leading cause of their cancer death. Establishing an accurate BC prognosis is very difficult because of its heterogeneity. Elevated TFF1 levels in serum were associated with development of BC, TFF1 expression was upregulated in BC compared to the healthy breast tissue.That expression of TFF1 was related to ER status of BC and that expression of TFF1 was lower in TNBC than in non-TNBC. |
molecular weight | The protein has a predicted MW of 33.3 kDa. Due to glycosylation, the protein migrates to 40-45 kDa based on Tris-Bis PAGE result. |
available size | 100 µg, 500 µg |
endotoxin | Less than 1EU per μg by the LAL method. |
Human TFF1 Protein 3869
$270.00 – $900.00
Summary
- Expression: HEK293
- Pure: Yes (HPLC)
- Amino Acid Range: Glu25-Phe84
Human TFF1 Protein 3869
protein |
---|
Size and concentration 100, 500µg and lyophilized |
Form Lyophilized |
Storage Instructions Valid for 12 months from date of receipt when stored at -80°C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Storage buffer Shipped at ambient temperature. |
Purity > 95% as determined by Tris-Bis PAGE |
target relevance |
---|
Breast cancer (BC) is the most common cancer in women and the second leading cause of their cancer death. Establishing an accurate BC prognosis is very difficult because of its heterogeneity. Elevated TFF1 levels in serum were associated with development of BC, TFF1 expression was upregulated in BC compared to the healthy breast tissue.That expression of TFF1 was related to ER status of BC and that expression of TFF1 was lower in TNBC than in non-TNBC. |
Protein names Trefoil factor 1 (Breast cancer estrogen-inducible protein) (PNR-2) (Polypeptide P1.A) (hP1.A) (Protein pS2) |
Gene names TFF1,TFF1 BCEI PS2 |
Mass 9606Da |
Function Stabilizer of the mucous gel overlying the gastrointestinal mucosa that provides a physical barrier against various noxious agents. May inhibit the growth of calcium oxalate crystals in urine. |
Subellular location Secreted . |
Tissues Found in stomach, with highest levels in the upper gastric mucosal cells (at protein level). Detected in goblet cells of the small and large intestine and rectum, small submucosal glands in the esophagus, mucous acini of the sublingual gland, submucosal glands of the trachea, and epithelial cells lining the exocrine pancreatic ducts but not in the remainder of the pancreas (at protein level). Scattered expression is detected in the epithelial cells of the gallbladder and submucosal glands of the vagina, and weak expression is observed in the bronchial goblet cells of the pseudostratified epithelia in the respiratory system (at protein level). Detected in urine (at protein level). Strongly expressed in breast cancer but at low levels in normal mammary tissue. It is regulated by estrogen in MCF-7 cells. Strong expression found in normal gastric mucosa and in the regenerative tissues surrounding ulcerous lesions of gastrointestinal tract, but lower expression found in gastric cancer (at protein level). |
Structure Heterodimer with GKN2; disulfide linked. |
Target Relevance information above includes information from UniProt accession: P04155 |
The UniProt Consortium |
Data
![]() |
The purity of Human TFF1 is greater than 95% as determined by SEC-HPLC. |
![]() |
Human TFF1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. |
Publications
Publications
pmid | title | authors | citation |
---|---|---|---|
We haven't added any publications to our database yet. |
Protocols
relevant to this product |
---|
Documents
# | ||
---|---|---|
Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information. |